BC Week In Review | Apr 18, 2016
Clinical News

ParvOryx: Phase I/IIa started

Oryx began an open-label, dose-escalation, German Phase I/IIa trial to evaluate 3 dose levels of ParvOryx in 7 patients with inoperable tumors having >=1 hepatic metastasis. Patients will receive IV ParvOryx on 4 consecutive days...
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG , are investigating co-administering the therapies with...
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
BC Week In Review | Sep 21, 2015
Clinical News

VicOryx: Phase I started

Oryx began the open-label, German Phase I VICORYX-2 trial to evaluate 100 ug subcutaneous VicOryx with the Montanide ISA-51 VG adjuvant in combination with cisplatin-based chemotherapy in 10 patients with HPV- and p16INK4a-positive cervical, vulvar,...
BC Week In Review | Jul 13, 2015
Clinical News

ParvOryx: Phase I/IIa data

The open-label, German Phase I/IIa ParvOryx01 trial in 18 patients with progressive primary or recurrent glioblastoma showed that ParvOryx was safe and induced “strong” cellular immune responses. Oryx GmbH & Co. KG , Baldham, Germany  ...
BC Week In Review | May 25, 2015
Clinical News

MicOryx: Additional Phase I/IIa data

Oryx said 1 heavily pretreated patient with bulky metastases who received MicOryx in an open-label, German Phase I/IIa trial achieved stable disease. The trial enrolled 22 patients with advanced MSI-H colorectal cancer who received standard...
BC Week In Review | Mar 16, 2015
Clinical News

MicOryx: Phase I/IIa data

An open-label Phase I/IIa trial in 22 patients with advanced MSI-H colorectal cancer who received standard chemotherapy showed that MicOryx was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG , Baldham,...
BC Week In Review | Mar 16, 2015
Clinical News

VicOryx: Phase I/IIa data

An open-label, German Phase I/IIa trial in 26 patients with p16INK4a-overexpressing HPV-positive cancer showed that once-weekly subcutaneous 100 ug VicOryx plus the Montanide ISA 51 VG adjuvant for the first 4 weeks of an 8-week...
BC Week In Review | Jun 9, 2008
Company News

Sepracor, Arrow International Group deal

Sepracor completed its previously announced acquisition of Arrow’s Oryx Pharmaceuticals Inc. subsidiary for $50 million up front and up to $20 million in Canadian regulatory milestones (see BioCentury, May 5). Sepracor Inc. (NASDAQ:SEPR), Marlborough, Mass....
BC Week In Review | May 5, 2008
Company News

Sepracor, Arrow International Group deal

Sepracor received an exclusive, worldwide license to use Arrow's stable steroid suspension formulations and other nebule technology to develop and commercialize inhaled therapeutics containing ciclesonide, ciclesonide/arformoterol and levalbuterol/ipratropium. Arrow will receive $1 million up front...
Items per page:
1 - 10 of 19
BC Week In Review | Apr 18, 2016
Clinical News

ParvOryx: Phase I/IIa started

Oryx began an open-label, dose-escalation, German Phase I/IIa trial to evaluate 3 dose levels of ParvOryx in 7 patients with inoperable tumors having >=1 hepatic metastasis. Patients will receive IV ParvOryx on 4 consecutive days...
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG , are investigating co-administering the therapies with...
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
BC Week In Review | Sep 21, 2015
Clinical News

VicOryx: Phase I started

Oryx began the open-label, German Phase I VICORYX-2 trial to evaluate 100 ug subcutaneous VicOryx with the Montanide ISA-51 VG adjuvant in combination with cisplatin-based chemotherapy in 10 patients with HPV- and p16INK4a-positive cervical, vulvar,...
BC Week In Review | Jul 13, 2015
Clinical News

ParvOryx: Phase I/IIa data

The open-label, German Phase I/IIa ParvOryx01 trial in 18 patients with progressive primary or recurrent glioblastoma showed that ParvOryx was safe and induced “strong” cellular immune responses. Oryx GmbH & Co. KG , Baldham, Germany  ...
BC Week In Review | May 25, 2015
Clinical News

MicOryx: Additional Phase I/IIa data

Oryx said 1 heavily pretreated patient with bulky metastases who received MicOryx in an open-label, German Phase I/IIa trial achieved stable disease. The trial enrolled 22 patients with advanced MSI-H colorectal cancer who received standard...
BC Week In Review | Mar 16, 2015
Clinical News

MicOryx: Phase I/IIa data

An open-label Phase I/IIa trial in 22 patients with advanced MSI-H colorectal cancer who received standard chemotherapy showed that MicOryx was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG , Baldham,...
BC Week In Review | Mar 16, 2015
Clinical News

VicOryx: Phase I/IIa data

An open-label, German Phase I/IIa trial in 26 patients with p16INK4a-overexpressing HPV-positive cancer showed that once-weekly subcutaneous 100 ug VicOryx plus the Montanide ISA 51 VG adjuvant for the first 4 weeks of an 8-week...
BC Week In Review | Jun 9, 2008
Company News

Sepracor, Arrow International Group deal

Sepracor completed its previously announced acquisition of Arrow’s Oryx Pharmaceuticals Inc. subsidiary for $50 million up front and up to $20 million in Canadian regulatory milestones (see BioCentury, May 5). Sepracor Inc. (NASDAQ:SEPR), Marlborough, Mass....
BC Week In Review | May 5, 2008
Company News

Sepracor, Arrow International Group deal

Sepracor received an exclusive, worldwide license to use Arrow's stable steroid suspension formulations and other nebule technology to develop and commercialize inhaled therapeutics containing ciclesonide, ciclesonide/arformoterol and levalbuterol/ipratropium. Arrow will receive $1 million up front...
Items per page:
1 - 10 of 19